

1 NSE, positively regulated by LINC00657-miR-93-5p axis, promotes small cell lung
2 cancer (SCLC) invasion and epithelial-mesenchymal transition (EMT) process

3

4 Lin Lu^{#*}, Zhiqiang Zha[#], Peiling Zhang, Dailing Li, Guolong Liu^{*}

5 Department of Medical Oncology, Guangzhou First People's Hospital, School of

6 Medicine, South China University of Technology, Guangzhou, Guangdong, China

7

8 [#]These authors contributed equally to this work.

9

10 **Correspondence to: Dr. Lin Lu, Guangzhou First People's Hospital, School of*

11 *Medicine, South China University of Technology, Guangzhou, Guangdong, China,*

12 *510180. Tel: +86-20-81045230, Fax: +86-20-81045230, E-mail: eylinlv@scut.edu.cn*

13 *or Dr. Guolong Liu, eygliu@scut.edu.cn*

14

15

16 **Abstract**

17 **Background:** Neuron specific enolase (NSE) is a specific biomarker for SCLC.

18 However, the biological roles and aberrant expression of NSE in SCLC have not been

19 well illustrated.

20 **Methods:** The expression of NSE, miR-93-5p and LINC00657 in SCLC tissues and

21 cell lines were detected using real time quantitative PCR (qRT-PCR) or

22 immunohistochemistry. CCK8 assay was performed to detect cell proliferation. Cell
23 migration and invasion capabilities were investigated by transwell assay.
24 Epithelial-mesenchymal transition (EMT) process was verified by detecting epithelial
25 marker E-cadherin and mesenchymal marker N-cadherin. The direct interactions
26 between miR-93-5p and NSE or LINC00657 were predicted by bioinformatics tools
27 and verified using dual luciferase reporter assay.

28 **Results:** Upregulated expression of NSE in SCLC tumor tissues were positively
29 associated with advanced tumor stage, distant metastasis and poor overall survival.
30 Overexpression of NSE promoted cell proliferation, migration, invasion and EMT in
31 SCLC cells, while silence of NSE inhibited these effects. Mechanically, NSE
32 expression was positively correlated with LINC00657, and negatively correlated with
33 miR-93-5p. Moreover, NSE was positively regulated by LINC00657 through
34 sponging of miR-93-5p. LINC00657 and miR-93-5p promoted SCLC cell migration,
35 invasion and EMT by NSE-mediated manner.

36 **Conclusion:** Overall, our study revealed a novel role of NSE in SCLC. NSE was
37 positively regulated by LINC00657 through competitively interacting with miR-93-5p,
38 which may be potential targets for SCLC patients.

39 **Keywords:** NSE, LINC00657, EMT, Small cell lung cancer.

40

41

42

43 **Introduction**

44 Small cell lung cancer, which accounts for 10-20% of lung cancer, is the most
45 malignant lung cancer subtype (1, 2). SCLC is sensitive to chemotherapy and
46 radiotherapy, but the patients are more prone to develop disease relapse and distant
47 metastasis (3). The 5-year survival rate of SCLC is below 5% (4). In addition, few
48 patients could get benefits from the targeted therapy and immunotherapy (5, 6).
49 Moreover, the mechanisms underlying the aggressive behaviors and low clinical
50 responses for immunotherapy haven't been elucidated. Therefore, understanding the
51 underlying mechanisms is of great importance for identifying novel treatment targets
52 for SCLC patients.

53 Neuron-specific enolase (NSE), also known as enolase 2 (NSE), is the most
54 reliable biomarker in the diagnosis of SCLC, due to its high specificity (7, 8). Serum
55 concentrations of NSE were positively correlated with larger tumor size, advanced
56 tumor stage and distant metastasis (9). Besides, NSE demonstrated a promising role in
57 predicting the chemotherapy and radiotherapy responses (10, 11). NSE could enhance
58 aerobic glycolysis to promote survival and proliferation of tumor cells (12-14). NSE
59 could be transferred to the cell surface, which resulted in activating survival
60 promoting signal pathway to promote tumor cell migration (15). However, the
61 biological functions and upstream regulatory factors of NSE have not been clearly
62 defined in SCLC.

63 Long non-coding RNA (lncRNA) , non-coding RNA longer than 200
64 nucleotides, demonstrated important roles in carcinogenesis (16, 17). LncRNAs could
65 modulate various biological functions by regulating mRNA expression through
66 sponging miRNAs(18, 19). In this study, we firstly studied the role of NSE in the
67 migration, invasion and EMT process of SCLC. We further identified
68 lncRNA/miRNA which could regulate the expression and function of NSE. Our study
69 would provide novel insight into the metastasis and poor OS for SCLC patients.

70

71 **Material and methods**

72 **Tissues specimens and Ethical statement**

73 This study involved normal lung tissues and SCLC tissue samples. Ethics
74 Committee of Guangzhou First People's Hospital approved this study. And all the
75 patients were informed. Here, normal tissues were collected from the
76 normal lung tissues surrounding tumors, which was histopathologically confirmed.

77 All the cancer patients were histopathologically confirmed and none patients have
78 received any prior anti-tumor therapies prior to the collection of the tissues. Patients
79 were staged according to the AJCC) Cancer Staging Manual (seventh edition).

80 **Cell lines and cell culture**

81 Human normal lung bronchial epithelial cell line 16HBE and SCLC cell lines
82 (H446, H69, H209) were purchased from the Chinese Academy of Science. The cells

83 were cultured in RMPI-1640 supplemented with 10% fetal bovine serum (FBS). All
84 the cell lines were cultured in a humidified atmosphere of 37°C containing 5% CO₂.

85 **Real time quantitative PCR**

86 Firstly, total RNA was extracted from tissue specimens and cell lines using
87 TRIzol reagent as previously described(20, 21). Then complementary DNA was
88 synthesized based on reverse transcription from total RNA using Takara cDNA
89 Synthesis Kit. Resulting cDNA was subjected to real time quantitative PCR using
90 SYBR green master mix. The sequences of the sense and antisense primers were as
91 follows: 5'-AGCCTCTACGGGCATCTATGA-3' (F) and 5'-
92 TTCTCAGTCCCATCCAACTCC-3' (R) for
93 NSE;5'-ATTTTTCCCTCGACACCCGAT-3' (F) and
94 5'-TCCCAGGCGTAGACCAAGA-3' (R) for E-cadherin;
95 5'-AGCCAACCTTAACTGAGGAGT-3' (F) and
96 5'-GGCAAGTTGATTGGAGGGATG-3' (R) for N-cadherin;
97 5'-TGATAGGATACATCTTGGACATGGA-3' (F) and
98 5'-AACCTAATGAACAAGTCCTGACATAACA-3' (R) for LINC00657;
99 5'-CTCCTCCTGTTCGACAGTCAGC-3' (F) and
100 5'-CCCAATACGACCAAATCCGTT-3' (R) for GAPDH;
101 5'-TTATGGGTCCTAGCCTGAC-3' (F) and 5'-CACTATTGCGGGCTGC-3' (R)
102 for U6. Comparative threshold cycle (2- $\Delta\Delta$ CT) method was used to calculate the

103 relative mRNA values. The relative expression levels of AP000695.2 were
104 normalized to the value of GAPDH.

105 **Immunohistochemistry**

106 Paraffin-embedded SCLC tissue sections from 68 cases of SCLC patients were
107 collected at Guangzhou First People's hospital. After antigen retrieval, the slides were
108 incubated with the primary antibody (NSE, 1:100, Abcam) overnight. Then
109 diaminobenzidine (DAB) was used for immunohistochemical staining following the
110 incubation with the secondary antibody. Then the slides were hematoxylin
111 counterstaining, dehydrated and sealed. Finally, the images were collected under a
112 microscope.

113 **Western blot**

114 Total proteins from tissues specimens and cell lines were extracted using RIPA
115 solution as previously described(20, 21). Briefly, total proteins were separated using
116 SDS-PAGE and transferred to PVDF membrane. After being blocked by non-fat milk,
117 the membranes were incubated with primary antibodies as follows: anti-NSE (Abcam,
118 ab16808, 1:2000.), anti- β -catenin (Proteintech, 66009-1-Ig, 1:5000), anti-E-cadherin
119 (Proteintech, 20874-1-AP, 1:5000), and anti-N-cadherin (Affinity, AF4039, 1:1000).
120 Then membranes were incubated with corresponding secondary antibodies and
121 detected using the enhanced chemiluminescence system.

122 **Bioinformatic analysis**

123 The interaction between LINC00657 and miR-93-5p were predicted using
124 starBase v3.0(22). The interaction between miR-93-5p and NSE were predicted in
125 miRBD (23, 24).

126 **Cell transfection**

127 The cDNA sequence of NSE or LINC00657 was subcloned into the pcDNA3.1
128 expression vector (Invitrogen, Shanghai). Indicated H446 cells were transfected with
129 miR-93-5p inhibitor or mimic (purchased from GenePharma) to knock down or
130 overexpress miR-93-5p. Cells transfected with scramble was used as negative control
131 (NC). All the transfection experiments were performed using Lipofectamine2000
132 (Invitrogen)

133 **Cell proliferation**

134 Cell proliferation capability was assessed using Cell Counting Kit-8 (CCK8)
135 assay. Briefly, 5000 cells in 100 μ L culture medium were seeded in a 96-well plate.
136 10 μ L CCK8 reagent was added and incubated at different time point (12, 24, 36, 48h).
137 The absorbance of each well was measured under a microplate reader at a wavelength
138 of 450 nm.

139 **Cell migration and invasion**

140 Cell migration and invasion capabilities were assessed using with or without
141 pre-packed Matrigel (BD Bioscience, USA). Briefly, indicated cells suspended in
142 serum-free medium were placed in upper chambers as a density of 1×10^5 cells per
143 chamber. After incubation for 12h or 24h, the cells in the upper chamber was removed,

144 fixed with 4% paraformaldehyde and stained using 0.1% crystal violet. Cell migrated
145 or invaded to the lower chamber were counted and photographed under an optical
146 microscope.

147 **Dual-luciferase reporter assay**

148 The sequences of target genes and mutation genes were synthesized by Sangon
149 Biotech (Shanghai). LINC00657-wild type (-WT) plasmid and LINC00657-mutated
150 (-mut) plasmid were co-transfected with NC or miR-93-5p mimic using
151 Lipofectamine2000 (Invitrogen). Similarly, wild-type and mutant 3'-UTR of NSE
152 were subcloned into the luciferase-containing vector pGL3-luciferase vector. Then the
153 wt or mut reporter plasmid was co-transfected with NC or miR-93-5p mimic using
154 Lipofectamine2000 (Invitrogen).

155 **Nuclear and cytoplasmic fractionation analysis**

156 Nuclear and cytoplasmic fractions were separated according to the
157 manufacturer's constructions (PARIS kit, Thermo Fisher Scientific, USA). Then
158 qRT-PCR was performed to detect the expression levels of LINC00657 in the nuclear
159 and cytoplasm. GAPDH and U6 were used as internal controls.

160 **Statistical analysis**

161 GraphPad Prism 7.0 software was utilized for all statistical analysis. The
162 relationships between NSE expression and various clinico-pathological parameters
163 were assessed using chi-square test. The correlations between two groups were
164 compared using student' t-test, one-way ANOVA, or Pearson correlation coefficient

165 analysis. A two-tailed p value < 0.05 was accepted as significant difference. These
166 experiments are repeated at least 3 times.

167

168 **Results**

169 **Upregulated NSE expression was correlated with poor survival of SCLC** 170 **patients.**

171 Serum NSE is an ideal biomarker for the diagnosis and treatment efficacy
172 monitoring in SCLC. However, the expression of NSE in tumor tissues and its
173 biological functions have not been well studied. In this study, we compared mRNA
174 expression levels NSE between 16 cases of normal tissues and 38 cases of human
175 SCLC tumor tissues. The qRT-PCR result showed that NSE expression was
176 significantly upregulated in SCLC tissues (Figure 1A, $P = 0.003$).

177 Immunohistochemistry confirmed the expression of NSE in SCLC tissues. Figure 1B
178 demonstrated the representative microscopic images of NSE expression. Among the
179 68 cases of SCLC tissue sections, there were 52 cases (76.47%) demonstrated positive
180 NSE expression. High NSE expression was positively correlated T stage ($P = 0.025$,
181 Table 1), advanced TNM stages ($P = 0.001$, Table 1), as well as distant metastasis (P
182 $= 0.015$, Table 1). Moreover, high expression of NSE was positively correlated with
183 poor overall survival of SCLC patients (Figure 1C. $P = 0.013$). These data indicated
184 that NSE acted as an oncogene, which might promote tumor progression and distant
185 metastasis in SCLC.

186 **NSE promoted cell migration, invasion and EMT of SCLC cells**

187 The expression of NSE in human bronchial epithelial cell 16HBE and different
188 SCLC cell lines were compared at mRNA and protein levels. As shown in Figure 2A
189 and B, relative NSE expression was the highest in H69 and lowest in H446. Therefore,
190 H69 and H446 were subjected to the subsequent cellular functions assays. To evaluate
191 the biological function of NSE in SCLC, NSE overexpression and knockdown cells
192 were constructed based on the differential expression of endogenous NSE expression.
193 H446 cells were transfected with a lentivirus vector to construct NSE overexpression
194 cells. H69 cells were transfected with short hairpin RNAs (shRNAs) to knock down
195 endogenous NSE expression. The relative expression of NSE after overexpression or
196 knockdown were verified using qRT-PCR (Figure 2C, $P < 0.05$).

197 The effect of NSE on cell proliferation was investigated using CCK8 assay. As
198 shown in Figure 2D, overexpression of NSE promoted SCLC cell proliferation ($P <$
199 0.001), while knockdown of NSE inhibited cell proliferation ($P < 0.001$). Cell
200 migration and invasion were investigated using transwell assay. Our results showed
201 that NSE overexpression promoted H446 cell migration and invasion. The numbers of
202 NSE overexpression cells migrated and invaded much more than control cells (Figure
203 2E). Knockdown of NSE significantly reduced the migration capability of H69 cells
204 (Figure 2F).

205 Moreover, western blot results demonstrated that overexpression of NSE
206 downregulated the expression of epithelial marker E-cadherin and upregulated the

207 expression of mesenchymal makers N-cadherin. In contrast, knockdown of NSE
208 upregulated the expression of E-cadherin and downregulated the expression of
209 N-cadherin (Figure 2G). Taken together, these data indicated that NSE could promote
210 the migration, invasion and EMT of SCLC cells.

211 **NSE expression was regulated by miR-93-5p**

212 The mechanism underlying the upregulated NSE expression in SCLC is largely
213 unknown, here we explored the miRNA which could modulate the expression of NSE.
214 The miRNA-mRNA interactions database starBase
215 (<http://starbase.sysu.edu.cn/index.php>) was applied to predict potential miRNAs that
216 could interact with NSE. And we found that miR-93-5p could target NSE mRNA
217 3'UTR (Figure 3A). The interaction between miR-93-5p and NSE was validated using
218 a dual luciferase reporter assay. As shown in Figure 3B, overexpression of miR-93-5p
219 significantly decreased the luciferase activity of the NSE-wild type (NSE-WT) ($P <$
220 0.001), but not the luciferase activity of the NSE-MUT. In addition, the mRNA
221 expression level of NSE was upregulated in cells transfected with miR-93-5p mimic
222 (Figure 3C, $P = 0.001$). While miR-93-5p inhibitor increased the mRNA expression
223 level of NSE (Figure 3C, $P = 0.002$). Moreover, the expression of miR-93-5p in
224 SCLC tissues and normal tissues were assessed using qRT-PCR. We found
225 significantly decreased expression of miR-93-5p in SCLC tumor tissues than in
226 normal tissues (Figure 3D, $P < 0.001$). Higher expression of miR-93-5p were detected
227 in SCLC cell lines while comparing with human normal lung bronchial epithelial cell

228 line 16HBE (Figure 3E, $P < 0.05$). Moreover, Pearson correlation coefficient analysis
229 demonstrated that there was negative correlation between NSE and miR-93-5p
230 expression based on their mRNA expression levels in the 38 cases of SCLC
231 specimens (Figure 3F, $P = 0.048$, $R^2 = 0.1046$). These data indicated that miR-93-5p
232 directly reduced the expression of NSE in SCLC cells.

233 **miR-93-5p inhibited cell migration, invasion and EMT of SCLC cell by**
234 **down-regulated the expression of NSE**

235 We next verified whether NSE was essential for the effect of miR-93-5p on the
236 cellular functions of SCLC cells. NSE overexpressed cells were transfected with
237 miR-93-5p mimic or control mimic. As shown in Figure 4A, overexpression of
238 miR-93-5p significantly decreased the cell proliferation capabilities of SCLC cells.
239 And overexpression of NSE partially abolished the inhibitory effect of miR-93-5p
240 mimic on cell proliferation (Figure 4A, $P < 0.01$). Transwell assay demonstrated that
241 treatment of miR-93-5p mimic significantly inhibited SCLC cell migration. And the
242 inhibitory effect of miR-93-5p mimic on cell migration could be suppressed by NSE
243 overexpression (Figure 4B). Similarly, invasion assay also demonstrated that the
244 inhibitory effect of miR-93-5p mimic on cell invasion could be partially abolished by
245 the overexpression of NSE (Figure 4B). Figure 4C shows the cell numbers migrated
246 or invaded. These data indicated that miR-93-5p exerted tumor suppressive effects by
247 downregulating NSE expression.

248 **LINC00657 acted as a sponge for miR-93-5p**

249 We further explored the potential lncRNAs that could interact with miR-93-5p.
250 According to starBase, we identified LINC00657 as a potential lncRNA (Figure 5A).
251 Since cytoplasmic lncRNAs could work as ceRNA and regulate the target gene
252 expression by sponging miRNA. We investigated the subcellular location of
253 LINC00657 using nuclear-cytoplasm fractionation assay. The results showed that
254 LINC00657 was mainly located in the cytoplasm of SCLC cells (Figure 5B).
255 Wild-type (LINC00657-WT) and mutated (LINC00657-MUT) miR-93-5p binding
256 sites were subcloned into dual-luciferase reporters. The luciferase assay results
257 showed that miR-93-5p mimics significantly inhibited the relative luciferase activity
258 of LINC00657-WT SCLC cells ($P = 0.006$), but exerted no effect on
259 LINC00657-MUT cells (Figure 5C). The expression of LINC00657 in SCLC tissues
260 and cell lines were detected using qRT-PCR. As shown in Figure 5D, LINC00657
261 expression was significantly upregulated in SCLC tumor tissues compared to normal
262 tissues (Figure 5D, $P = 0.001$). And the expression of LINC00657 was much higher in
263 SCLC cells than normal cell 16HBE (Figure 5E, $P < 0.05$). In addition, LINC00657
264 overexpression downregulated the expression of miR-93-5p ($P = 0.006$) and
265 upregulated the expression of NSE ($P = 0.004$) (Figure 5F), while knockdown of
266 LINC00657 upregulated the expression of miR-93-5p ($P = 0.002$) and downregulated
267 the expression of NSE ($P = 0.002$) (Figure 5G). We further confirmed the correlation
268 between LINC00657 and miR-93-5p based on the mRNA data generated from the 38
269 cases of SCLC tumor tissues. As shown in Figure 5H, Pearson correlation coefficient

270 result showed that miR-93-5p expression was negatively correlated with LINC00657
271 ($R^2=0.2086$, $P = 0.003$). Meanwhile, the expression of LINC00657 was positively
272 correlated with the expression of NSE ($R^2=0.4323$, $P < 0.001$). Taken together, these
273 data indicated that LINC00657 might act as a sponge of miR-93-5p that directly target
274 NSE in SCLC.

275 **LINC00657 modulated cell proliferation, migration, invasion and EMT of SCLC**
276 **cells by regulating NSE**

277 To further confirm the effect of LINC00657 in promoting the EMT process by
278 regulating NSE, SCLC cell line H69 were transfected with siLINC00657 and/or NSE
279 overexpression plasmid. Transwell assay indicated that silence of LINC0065
280 repressed SCLC cell migration and invasion. And the effect of LINC0065 on cell
281 migration and invasion could be reversed by NSE overexpression (Figure 6A and B).
282 Mechanically, silence of LINC00657 significantly upregulated the expression of
283 E-cadherin and downregulated the expression of N-cadherin. And NSE
284 overexpression could reverse the inhibitory effects of LINC0065 on the EMT process
285 of SCLC cells, which was indicated by E-cadherin downregulation and N-cadherin
286 upregulation (Figure 6C). In addition, NSE overexpression could reverse the effect of
287 LINC0065 on cell proliferation of SCLC cells (Figure 5D). These results indicated
288 that LINC00657 could modulate NSE to promote the migration, invasion and EMT of
289 SCLC cells.

290

291 **Discussion**

292 NSE is mainly expressed in neurons and neuroendocrine cells, which is generally
293 accepted as a specific biomarker for neuroendocrine tumors, such as SCLC (25, 26).
294 For a long time, most of the studies focused on the role of NSE as a biomarker in
295 SCLC. Here, we discovered that upregulated expression of NSE was positively
296 correlated with advanced tumor stage, distant metastasis and poor overall survival of
297 SCLC patients. Epithelial-mesenchymal transition (EMT) is an important process for
298 tumor cell invasiveness and metastasis initiation, by which tumor cells lose cell-cell
299 adhesion and enable tumor cell invasion (27). Tumor cells gained EMT process
300 largely contributed to tumor cell metastasis, gain of stem cell-like phenotype and drug
301 resistance (28, 29). Here, our results indicated that modulation NSE expression could
302 regulate SCLC cell migration, invasion and the expression of EMT makers, such as
303 E-cadherin and N-cadherin. The modulation of NSE on EMT process might
304 contribute to the enhanced migration and invasion capabilities of SCLC cells, as well
305 as the distant metastasis. And our previous study also found that NSE could activate
306 the wnt/beta-catenin pathway and promote the EMT process and tumor metastasis of
307 SCLC cells(30). However, the mechanisms contributing to the upregulated expression
308 of NSE in SCLC remain largely unknown.

309 miRNA-mRNA interactions could inhibit the translation or degrade targeted
310 mRNAs to downregulated the expression of target genes (31, 32). The miRNA-gene
311 interactions were involved in multiple cellular processes during tumor development,

312 which including cell proliferation, cell migration, cell invasion, chemo-resistance,
313 tumor relapse and distant metastasis (33-35). Moreover, miRNAs were correlated
314 with chemoresistance, proliferation and poor outcome of SCLC such as
315 miR-886-3p(36), miR-495(37). Thus, we next explored the potential miRNA which
316 could interact with NSE and regulate the expression of NSE. According to
317 bioinformatics analysis tool and dual luciferase reporter assay, we verified that
318 miR-93-5p could directly interact with NSE. Downregulated expression of miR-93-5p
319 was detected in SCLC tumor tissues and cell lines. There was a negative correlation
320 between miR-93-5p expression and NSE expression. The relative expression levels of
321 NSE were modulated by overexpression or knockdown of miR-93-5p. miR-93-5p, as
322 a circulating miRNA, functioned as diagnostic or prognostic biomarker in multiple
323 malignancies (38). Consistently, multiple studies also revealed that down-regulated
324 expression of miR-93-5p was detected in tumor tissues and cell lines, such as
325 colorectal cancer, gastric cancer (39-42).

326 There are multiple target genes for each miRNA (43). miR-93-5p could regulate
327 HIF-1A/AXL signaling pathways to facilitate the progression and EMT of colorectal
328 cancer (39). Liu et al found that downregulated expression of miR-93-5p could
329 upregulate the expression of AHNAK to promote the progression of gastric cancer
330 (41). Chen et al revealed that miR-93-5p functioned as a tumor suppressor by
331 suppressing the expression of programmed death ligand 1 (PD-L1) (40). Here, we

332 found that miR-93-5p inhibited cell proliferation, migration, invasion and EMT by
333 directly targeting NSE.

334 Competitive endogenous RNA (ceRNA) regulatory network indicated the
335 crosstalk between lncRNAs, miRNAs and mRNAs, in which mRNAs expression
336 could be regulated by lncRNAs through sponging miRNAs (44, 45). Moreover,
337 lncRNAs also have been found that was relevant to cellular proliferation, invasiveness,
338 tumorigenesis and clinical relapse in SCLC such as lncRNA HOTAIR(46), lncRNA
339 H19(47). Thus, we further explored lncRNAs which could interact with miR-93-5p to
340 regulate the expression of NSE. Through bioinformatics analysis we found the
341 potential interaction between miR-93-5p and LINC00657, which was further verified
342 by dual luciferase assay. Overexpression of LINC00657 downregulated the
343 expression of miR-93-5p and upregulated the expression of NSE. In contrast,
344 knockdown of LINC00657 upregulated the expression of miR-93-5p and
345 downregulated expression of NSE. Moreover, LINC00657 was mainly localized in
346 cytoplasm and could be detected in exosomes (48). This suggested that LINC00657
347 could function as ceRNA. The role of LINC00657 in tumor development was
348 controversial. Overexpression of LINC00657 repressed hepatocellular carcinoma cell
349 growth(49). On the contrary, studies in colorectal cancer, breast cancer, oral
350 squamous cell carcinoma, glioblastoma revealed that LINC00657 worked as an
351 oncogenic lncRNA (50-52). Here, we found upregulated expression of LINC00657 in
352 SCLC tumor tissues and cell lines. A positive correlation between NSE and

353 LINC00657 expression levels was found in SCLC tumor tissues, while a negative
354 correlation between NSE and miR-93-5p was observed.

355 Targeted mRNA expression could be regulated by lncRNAs/miRNA axis,
356 which resulted in altering the biological activities of tumor cells. Moreover, the
357 biological functions of LINC00657/ miR-93-5p/NSE in SCLC were further explored.
358 Our results showed that overexpression of NSE abolished the inhibitory effect of
359 LINC00657 on the migration, invasion and EMT of SCLC cells. Consistently, Zhang
360 et al found that LINC00657 promoted the invasiveness and metastasis of
361 osteosarcoma via regulating miR-106a and PD-L1 (53). LINC00657 upregulated the
362 expression of EMT-related target gene ZEB1 (54). Bi et al found that LINC00657
363 could act as a ceRNA by sponging miRNA-433 to upregulated PAK4 expression to
364 promote invasion and progression of pancreatic ductal adenocarcinoma (55).
365 Therefore, LINC00657, miR-93-5p and NSE formed regulatory axis for the EMT
366 process regulation in SCLC.

367 The present study has several limitations. For example, we predicated the
368 interaction of LINC00657 and miR-93-5p by starBase, but there is still a lack of direct
369 evidence of physical interaction of LINC00657 and miR-93-5p.

370 In conclusion, proteins, miRNAs and lncRNAs all demonstrated promising
371 noninvasive biomarkers for SCLC diagnosis and treatment surveillance. Here, we
372 identified LINC00657/ miR-93-5p/NSE in regulating the migration, invasion and
373 EMT of SCLC. LINC00657 positively regulated the expression of NSE by sponging

374 miR-93-5p in SCLC cells, thereby promoting EMT process, migration and invasion of
375 SCLC cells. These results provided us with novel insights about the progression of
376 SCLC. Our study will contribute to the exploring the biomarkers (LINC00657,
377 miR-93-5p and NSE) for predicting prognosis and therapeutic targets in SCLC.

378

379 **Abbreviations**

380 Neuron specific enolase, NSE

381 Small cell lung cancer, SCLC

382 Epithelial-mesenchymal transition, EMT

383 Real time quantitative PCR, qRT-PCR

384 Diaminobenzidine, DAB

385 Empty vector, EV.

386 **Data Availability**

387 All data in our study are available from the corresponding authors upon reasonable
388 request.

389 **Conflicts of Interest**

390 All the authors declare that there are no conflicts of interest.

391 **Funding Statement**

392 This research was funded by the National Natural Science Foundation of China (No.
393 81672900), Guangzhou Planned Project of Science and Technology (No.
394 201904010427 and No.201707010262) and Guangzhou General Science and

395 technology project of Health and Family Planning (grant number 20201A011007).

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416 **Tables**417 **Table 1.** The relationships between NSE expression and clinicopathological
418 parameters in SCLC

Characteristics	N	NSE		X ²	P-value
		High expression	Low expression		
Age				0.793	0.373
≥60	30	22	8		
<60	38	24	14		
Gender				0.048	0.826
Male	42	28	14		
Female	26	18	8		
Smoking				1.635	0.201
Never-smoker	50	36	14		
Smoker	18	10	8		
T stage				5.029	0.025*
T1+2	33	18	15		
T3+4	35	28	7		
N stage				0.006	0.936
No	12	8	4		
Yes	56	38	18		
M stage				5.921	0.015*
M0	42	26	16		
M1	26	20	6		
TNM stage				10.76	0.001*
I+II	33	16	17		
III+IV	35	30	5		

419

420

421

422

423 **Figure legends**424 **Figure 1.** Upregulated expression of NSE was positively correlated with poor425 **overall survival of SCLC patients.** (A) Real time quantitative PCR (qRT-PCR) was

426 performed to compare the expression of NSE in SCLC tumor tissues (N=38) and
427 normal tissues (N=16). (B) The protein expression of NSE in SCLC tumor tissues
428 were detected using immunohistochemistry (N=68). Representative images of high
429 NSE expression and low NSE expression were demonstrated (magnification, x20). (C)
430 Kaplan-Meier survival curve of the NSE expression in predicting overall survival (OS)
431 of SCLC patients.

432 **Figure 2. NSE promoted the proliferation, migration and invasion of SCLC cells.**

433 The relative mRNA expression levels of NSE in human bronchial epithelial cell
434 16HBE and various SCLC cell lines were detected using real time quantitative PCR
435 (A). (B) The relative protein express levels of NSE were measured by western blot.
436 **And quantification of the relative protein amount was shown in the lower panel.** (C)
437 Real time quantitative PCR confirmed the expression of NSE after being
438 overexpressed or knockdown. (D) The effect of NSE on the proliferation capabilities
439 of SCLC cells were assessed using CCK8 assay. Transwell assay was performed to
440 investigate the effect of NSE on the migration and invasion of SCLC cells. (E)
441 Overexpression of NSE promoted cell migration and invasion of H446 cells. (F)
442 Knockdown of NSE significantly inhibited cell migration. (G)Western blot results
443 demonstrated overexpression of NSE promoted the EMT process by down-regulating
444 the expression of E-cadherin and upregulating the expression of N-cadherin, while
445 silencing NSE upregulated the expression of E-cadherin and downregulated the

446 expression of N-cadherin. And quantification of the relative protein amount was
447 shown in the lower panel

448 **Figure 3. NSE is a target of miR-93-5p in SCLC.** (A) The binding site between
449 NSE and miR-93-5p was predicted by bioinformatics
450 software. (B) Luciferase reporter assay confirmed the association between NSE and
451 miR-93-5p. (C) Real time quantitative PCR demonstrated that miR-93-5p mimics
452 downregulated the expression of NSE, while miR-93-5p inhibitor upregulated the
453 expression of NSE. (D) qRT-PCR was performed to detect the expression of
454 miR-93-5p between SCLC tumor tissues and normal tissues. (E) The expression of
455 miR-93-5p in normal cell line 16HBE and SCLC cell lines were compared using
456 qRT-PCR. (F) The negative correlation between NSE and miR-93-5p was compared
457 using Pearson correlation coefficient in 38 SCLC tissues.

458 **Figure 4. The tumor suppressive capabilities of miR-93-5p was reversed by NSE**
459 **overexpression.** SCLC cell line H69 was transfected with NSE overexpressed
460 plasmids or/and miR-93-5p mimics. (A) Cell proliferation capabilities were assessed
461 using CCK8 assay. (B, C) Cell migration and invasion capabilities were evaluated
462 using transwell assay. (D) The expression levels of NSE in indicated cells were
463 assessed using western blot analysis.

464 **Figure 5. LINC00657 acted as a sponge for miR-93-5p.** (A) Bioinformatics
465 identified that LINC00657 could bind to miR-93-5p. (B) Cellular location of
466 LINC00657 was detected using qRT-PCR. (C) Dual Luciferase reporter assay

467 revealed the association between LINC00657 and miR-93-5p. (D) The expression of
468 LINC00657 between SCLC tumor tissues and normal tissues were compared using
469 qRT-PCR. (E) The expression of LINC00657 in normal cell line and SCLC cell lines
470 H446, H69 was compared using qRT-PCR. The mRNA expression of miR-93-5p and
471 NSE were assessed in LINC00657-overexpressed cells (F) and LINC00657
472 knockdown cells (G) . (H) Pearson correlation coefficient revealed that there was
473 negative correlation between LINC00657 and miR-93-5p. And there was positive
474 correlation between LINC00657 and NSE. The data were based on the expression of
475 LINC00657 and miR-93-5p in the 38 cases of SCLC tumor tissues.

476 **Figure 6. LINC00657 promotes the migration and invasion of SCLC cells by**
477 **upregulating the expression of NSE.** SCLC cell lung H69 was transfected with
478 si-LINC00657 and/or NSE overexpression vector. (A, B) Cell migration and invasion
479 capabilities were investigated using transwell assay. (C) The expression of NSE,
480 EMT-related markers (E-cadherin and N-cadherin) were detected using western blot.
481 **And the quantification of the relative protein amount was shown in the lower panel.**
482 (D) Cell proliferation viabilities were assessed using CCK8 assay.

483 **Figure 7. Working model.** NSE was positively regulated by LINC00657 through
484 sponging of miR-93-5p and promoted migration, invasion and EMT of SCLC cells.

485

486 **References**

487 1. J V, L C, C D, JY D, C F-F, E L, et al. 2nd ESMO Consensus Conference on Lung Cancer:
488 early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up.

- 489 Annals of oncology : official journal of the European Society for Medical Oncology.
490 2014;25(8):1462-74.
- 491 2. BC B, CS DC. Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clinics in
492 chest medicine. 2020;41(1):1-24.
- 493 3. A S, H M, M H, I L, I M, F B, et al. Association of Chemoradiotherapy With Outcomes
494 Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of
495 a Randomized Clinical Trial. JAMA oncology. 2019;5(3):e185335.
- 496 4. MB S, A N, P W, KR S, ZJ T, AA C. Temporal trends from 1986 to 2008 in overall survival
497 of small cell lung cancer patients. Lung cancer (Amsterdam, Netherlands). 2014;86(1):14-21.
- 498 5. D C, V V, RR P, HB B, MA C, JW W. Absolute Lymphocyte Count Predicts Abscopal
499 Responses and Outcomes in Patients Receiving Combined Immunotherapy and Radiation
500 Therapy: Analysis of 3 Phase 1/2 Trials. International journal of radiation oncology, biology,
501 physics. 2020.
- 502 6. H Z, CL C, R D, MG O, J D, B D, et al. CDK7 Inhibition Potentiates Genome Instability
503 Triggering Anti-tumor Immunity in Small Cell Lung Cancer. Cancer cell. 2020;37(1):37-54.e9.
- 504 7. B W, YJ H, YX T, RN Y, YR Z, H Q. Clinical utility of haptoglobin in combination with CEA,
505 NSE and CYFRA21-1 for diagnosis of lung cancer. Asian Pacific journal of cancer prevention :
506 APJCP. 2014;15(22):9611-4.
- 507 8. ZF J, M W, JL X. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE
508 improved its diagnostic value for lung cancer. Life sciences. 2018;194:1-6.
- 509 9. Z H, D X, F Z, Y Y, L S. Pro-gastrin-releasing peptide and neuron-specific enolase: useful
510 predictors of response to chemotherapy and survival in patients with small cell lung cancer.
511 Clinical & translational oncology : official publication of the Federation of Spanish Oncology
512 Societies and of the National Cancer Institute of Mexico. 2016;18(10):1019-25.
- 513 10. L W, D W, G Z, Y Y, L D, Z D, et al. Clinical evaluation and therapeutic monitoring value
514 of serum tumor markers in lung cancer. The International journal of biological markers.
515 2016;31(1):e80-7.
- 516 11. S H, J vP, E D, T D, B F, A M, et al. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA
517 in monitoring first-line chemotherapy of small cell lung cancer. Clinical cancer research : an
518 official journal of the American Association for Cancer Research. 2008;14(23):7813-21.
- 519 12. E S, S D. Analysis and interpretation of transcriptomic data obtained from extended
520 Warburg effect genes in patients with clear cell renal cell carcinoma. Oncoscience.
521 2015;2(2):151-86.
- 522 13. A A, C W. Glucose metabolism in cancer cells. Current opinion in clinical nutrition and
523 metabolic care. 2010;13(4):466-70.
- 524 14. T L, A L. Glutamine Metabolism in Cancer. Advances in experimental medicine and
525 biology. 2018;1063:13-32.
- 526 15. T V, J K. Gamma-enolase: a well-known tumour marker, with a less-known role in cancer.
527 Radiology and oncology. 2015;49(3):217-26.
- 528 16. McCabe E, Rasmussen T. lncRNA involvement in cancer stem cell function and
529 epithelial-mesenchymal transitions. Seminars in cancer biology. 2020.
- 530 17. Lucere K, O'Malley M, Diermeier S. Functional Screening Techniques to Identify Long

531 Non-Coding RNAs as Therapeutic Targets in Cancer. *Cancers*. 2020;12(12).

532 18. Zhou C, Duan S. The Role of Long Non-Coding RNA NNT-AS1 in Neoplastic Disease.
533 *Cancers*. 2020;12(11).

534 19. Huang M, Zhu T, Li L, Xie P, Li X, Zhou H, et al. LncRNAs and CircRNAs from the same
535 gene: Masterpieces of RNA splicing. *Cancer letters*. 2018;415:49-57.

536 20. Lu L, Wang P, Zou Y, Zha Z, Huang H, Guan M, et al. IL-1 β Promotes Stemness of
537 Tumor Cells by Activating Smad/ID1 Signaling Pathway. *International journal of medical
538 sciences*. 2020;17(9):1257-68.

539 21. Lu L, Du H, Huang H, Wang C, Wang P, Zha Z, et al. CCR9 Promotes Migration and
540 Invasion of Lung Adenocarcinoma Cancer Stem Cells. *International journal of medical
541 sciences*. 2020;17(7):912-20.

542 22. Li J, Liu S, Zhou H, Qu L, Yang J. starBase v2.0: decoding miRNA-ceRNA,
543 miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data.
544 *Nucleic acids research*. 2014;42:D92-7.

545 23. Chen Y, Wang X. miRDB: an online database for prediction of functional microRNA
546 targets. *Nucleic acids research*. 2020;48:D127-D31.

547 24. Liu W, Wang X. Prediction of functional microRNA targets by integrative modeling of
548 microRNA binding and target expression data. *Genome biology*. 2019;20(1):18.

549 25. CM X, YL L, S L, ZX L, L J, GX Z, et al. Multifunctional neuron-specific enolase: its role in
550 lung diseases. *Bioscience reports*. 2019;39(11).

551 26. PJ M, AM P, FK G. Functional properties of neuronal and glial isoenzymes of brain
552 enolase. *Journal of neurochemistry*. 1978;31(3):727-32.

553 27. B R, M C, G Y, H W, M F, L Y, et al. Tumor microenvironment participates in metastasis
554 of pancreatic cancer. *Molecular cancer*. 2018;17(1):108.

555 28. A S, J S. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war
556 on cancer. *Oncogene*. 2010;29(34):4741-51.

557 29. X Z, JL C, J K, M S, J K, H S, et al. Epithelial-to-mesenchymal transition is dispensable
558 for metastasis but induces chemoresistance in pancreatic cancer. *Nature*.
559 2015;527(7579):525-30.

560 30. Zha Z, Li D, Zhang P, Wang P, Fang X, Liu X, et al. Neuron specific enolase promotes
561 tumor metastasis by activating the Wnt/ β -catenin pathway in small cell lung cancer.
562 *Translational oncology*. 2021;14(4):101039.

563 31. DP B. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell*.
564 2004;116(2):281-97.

565 32. EF F, AE P. MicroRNA biogenesis: regulating the regulators. *Critical reviews in
566 biochemistry and molecular biology*. 2013;48(1):51-68.

567 33. EJ D, L L-B, N S, S DM, K O, A T, et al. Plasma microRNAs as biomarkers of pancreatic
568 cancer risk in a prospective cohort study. *International journal of cancer*. 2017;141(5):905-15.

569 34. D H, J L, H W, X S, J H, Y G, et al. Circular RNA circMTO1 acts as the sponge of
570 microRNA-9 to suppress hepatocellular carcinoma progression. *Hepatology (Baltimore, Md)*.
571 2017;66(4):1151-64.

572 35. DL L, LL L, LL D, Y L, XY B, BF L, et al. miR-17-5p and miR-20a-5p suppress

573 postoperative metastasis of hepatocellular carcinoma via blocking HGF/ERBB3-NF-κB
574 positive feedback loop. *Theranostics*. 2020;10(8):3668-83.

575 36. Cao J, Song Y, Bi N, Shen J, Liu W, Fan J, et al. DNA methylation-mediated repression
576 of miR-886-3p predicts poor outcome of human small cell lung cancer. *Cancer research*.
577 2013;73(11):3326-35.

578 37. Ye M, Wei T, Wang Q, Sun Y, Tang R, Guo L, et al. TSPAN12 promotes chemoresistance
579 and proliferation of SCLC under the regulation of miR-495. *Biochemical and biophysical
580 research communications*. 2017;486(2):349-56.

581 38. AH Z, PJS O, J A, JS M, TF H. Circulating miR-141 and miR-375 are associated with
582 treatment outcome in metastatic castration resistant prostate cancer. *Scientific reports*.
583 2020;10(1):227.

584 39. LG Y, MZ C, J Z, XY L, QL S. LncRNA XIST modulates HIF-1A/AXL signaling pathway by
585 inhibiting miR-93-5p in colorectal cancer. *Molecular genetics & genomic medicine*.
586 2020:e1112.

587 40. YL C, GX W, BA L, JS H. MicroRNA-93-5p expression in tumor tissue and its tumor
588 suppressor function via targeting programmed death ligand-1 in colorectal cancer. *Cell
589 biology international*. 2020.

590 41. ZM L, XL Y, F J, YC P, L Z. Matriline involves in the progression of gastric cancer through
591 inhibiting miR-93-5p and upregulating the expression of target gene AHNAK. *Journal of
592 cellular biochemistry*. 2020;121(3):2467-77.

593 42. E S, X W, X L, M L, L Z, G Z, et al. MicroRNA-93-5p promotes epithelial-mesenchymal
594 transition in gastric cancer by repressing tumor suppressor AHNAK expression. *Cancer cell
595 international*. 2020;20:76.

596 43. MS E, PA S. Emerging roles for natural microRNA sponges. *Current biology : CB*.
597 2010;20(19):R858-61.

598 44. X C, Z W, F T, X D, G W, R Z. lncRNA UCA1 Promotes Gefitinib Resistance as a ceRNA
599 to Target FOSL2 by Sponging miR-143 in Non-small Cell Lung Cancer. *Molecular therapy
600 Nucleic acids*. 2020;19:643-53.

601 45. J Y, Q Q, X Q, J Y, Y J, M Y, et al. Long noncoding RNA LCAT1 functions as a ceRNA to
602 regulate RAC1 function by sponging miR-4715-5p in lung cancer. *Molecular cancer*.
603 2019;18(1):171.

604 46. Ono H, Motoi N, Nagano H, Miyauchi E, Ushijima M, Matsuura M, et al. Long noncoding
605 RNA HOTAIR is relevant to cellular proliferation, invasiveness, and clinical relapse in
606 small-cell lung cancer. *Cancer medicine*. 2014;3(3):632-42.

607 47. Li X, Lv F, Li F, Du M, Liang Y, Ju S, et al. Long Non coding RNA H19 Facilitates Small
608 Cell Lung Cancer Tumorigenesis Through miR-140-5p/FGF9 Axis. *OncoTargets and therapy*.
609 2020;13:3525-34.

610 48. X L, Z G, Y H, X Y, Z W, L Z, et al. Comprehensive analysis of dysregulated exosomal
611 long non-coding RNA networks associated with arteriovenous malformations. *Gene*.
612 2020;738:144482.

613 49. Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to

614 know and the path forward. *Nature reviews Cancer*. 2017;17(12):725-37.

615 50. H L, J L, P K, X D, B C, Y W, et al. Long non-coding RNAs as prognostic markers in
616 human breast cancer. *Oncotarget*. 2016;7(15):20584-96.

617 51. FY X, X X, XD H. LINC00657 promotes malignant progression of oral squamous cell
618 carcinoma via regulating microRNA-150. *European review for medical and pharmacological*
619 *sciences*. 2020;24(5):2482-90.

620 52. L C, L Y, J L, S S, H Y, F H, et al. Long intergenic non-coding LINC00657 regulates
621 tumorigenesis of glioblastoma by acting as a molecular sponge of miR-190a-3p. *Aging*.
622 2019;11(5):1456-70.

623 53. J Z, X C, M Z, C Z, Y H, D C, et al. LINC00657 activates PD-L1 to promote osteosarcoma
624 metastasis via miR-106a. *Journal of cellular biochemistry*. 2020.

625 54. F S, H Z, L Z, W L, Y Z, X X. LINC00657 expedites neuropathic pain development by
626 modulating miR-136/ZEB1 axis in a rat model. *Journal of cellular biochemistry*.
627 2019;120(1):1000-10.

628 55. S B, Y W, H F, Q L. Long noncoding RNA LINC00657 enhances the malignancy of
629 pancreatic ductal adenocarcinoma by acting as a competing endogenous RNA on
630 microRNA-433 to increase PAK4 expression. *Cell cycle (Georgetown, Tex)*.
631 2020;19(7):801-16.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 6

637

638

639

640

641




Figure 7